Medigene and BioNTech announce global collaboration to advance T cell receptor immunotherapies against cancer

Planegg/Martinsried – Medigene AG (FSE: MDG1, Prime Standard, Medigene), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years.

BioNTech will acquire Medigene’s next generation preclinical TCR program, which combines TCR-4 of Medigene’s MDG10XX program targeting PRAME with Medigene’s proprietary PD1-41BB switch receptor technology. BioNTech will also obtain the exclusive option to acquire additional existing TCRs in Medigene’s discovery pipeline and will receive licenses to the company’s PD1-41BB switch receptor and precision pairing library. This has the potential to augment TCR cell therapy efficacy and can be applied to all BioNTech cell therapy programs. In addition, Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech.

Under the terms of the agreement, Medigene will receive EUR 26 million upfront, as well as research funding for the period of the collaboration. BioNTech will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR therapies resulting from this research collaboration. Medigene will be eligible to receive development, regulatory and commercial milestone payments up to a triple digit million EUR amount per program in addition to tiered deferred option payments on global net sales for products based on TCRs arising from the collaboration and royalties on products utilizing at least one of the licensed technologies.

With the upfront payment, Medigene’s financing is secured into Q4 2024. Nevertheless, Medigene will continue to evaluate financing options such as capital measures or new partnerships.

(end)

emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
country: Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: investor@medigene.com
website: www.medigene.com

ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20220221030 ]

This site is registered on wpml.org as a development site.